Chicago, IL (May 7, 2017) -- Researchers have found that taking an enzyme tablet while consuming foods containing gluten prevents a significant amount of it from entering the small intestine. This could enable gluten-sensitive patients to ingest small quantities of gluten without experiencing symptoms, such as bloating, diarrhea and abdominal pain.
The encouraging results from the enzyme known as aspergillus niger-derived prolyl endoprotease (AN-PEP) were presented at Digestive Disease Week® (DDW) 2017 , the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
"This substance allows gluten-sensitive patients to feel safer, for example, when they are out with friends at a restaurant and can't be sure whether something is 100 percent gluten-free," said Julia König, PhD, the study's lead author and post-doctoral research fellow at the School of Medical Sciences at University of Örebro, Sweden. "Since even small amounts of gluten can affect gluten-sensitive patients, this supplement can play an important role in addressing the residual gluten that is often the cause of uncomfortable symptoms."
Previous studies had shown that AN-PEP could break down gluten when it was intragastrically infused in a liquid meal through a feeding tube. This is the first study involving a normal meal: 18 self-reported gluten-sensitive patients ate a porridge that included two crumbled wheat cookies containing gluten. They also took either a high dose or low dose of AN-PEP, or a placebo. Researchers then measured gluten levels in the stomach and small intestine over the course of three hours.
The study found that AN-PEP, in both high and low doses, broke down gluten in both the stomach and the first part of the small intestine, or duodenum. In the stomach, gluten levels in both the high- and low-dose groups were 85 percent lower than in the placebo group. Once the food reached the duodenum, gluten levels were reduced by 81 percent in the high dose group and 87 percent in the low dose group versus placebo.
"Studies show that even when following a gluten-free diet, unintentional gluten intake can still occur, depending on how strict a gluten-free dieter is," added Dr. König. "Our results suggest that this enzyme can potentially reduce the side effects that occur when gluten-sensitive individuals accidentally eat a little gluten. We are not suggesting that AN-PEP will give these individuals the ability to eat pizza or pasta, sources of large amounts of gluten, but it might make them feel better if they mistakenly ingest gluten."
Dr. König noted that her team did not test the enzyme on celiac disease patients, because even small amounts of gluten can cause long-term harm in these individuals. Because of that, she does not recommend celiac patients view this enzyme as a way to start eating any gluten.
AN-PEP is currently available in the U.S. as a supplement developed by DSM, a Dutch multinational firm that provided the enzyme for the study. They did not provide any other support for this work.
Dr. Julia König will present data from the study, "Aspergillus niger-derived enzyme degrades gluten in the stomach of gluten-sensitive subjects" abstract Su1137, on Sunday, May 7, at 9:30 a.m. CT, in South Hall of McCormick Place. For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.ddw.org/press. DSM provided the enzyme for the study.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 6-9, 2017, at McCormick Place, Chicago. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at http://www.ddw.org.